Research programme: anti-infectives - deCODE genetics/Elitra
Alternative Names: Anti-infectives research programme - deCODE genetics/ElitraLatest Information Update: 02 Oct 2021
At a glance
- Originator deCODE genetics; Elitra Pharmaceuticals (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 19 Apr 2007 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 19 Apr 2007 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 22 Mar 2005 No development reported - Preclinical for Bacterial infections in USA (unspecified route)